Table 1 Summary of the patient baseline characteristics and clinical features
From: Fingerprint sign in Vogt-Koyanagi-Harada disease: a case series
Case | Eye | Age, years/Gender | Comorbidities | Time treatment, days1 | Treatment | VA baseline | VA last follow-up | Acute phase2 | Non-acute phase3 | Follow-up, months |
|---|---|---|---|---|---|---|---|---|---|---|
1 | OD | 39/F | None | 27 | Initial high-dose CE and slow tapering AZA at M1 MMF at M24 | CF | 20/20 | Optic disc hyperemia, macular SD | Anterior uveitis recurrence at M24 SGF | 43 |
OS | HM | 20/20 | Optic disc hyperemia, macular SD | Anterior uveitis recurrence at M24 CNV at M24 SGF | ||||||
2 | OD | 26/F | None | 14 | Initial high-dose CE and slow tapering AZA at M1 | HM | 20/20 | Optic disc hyperemia, macular SD | CNV at M12 SGF | 53 |
OS | CF | 20/20 | Optic disc hyperemia, macular SD | CNV at M12 SGF | ||||||
3 | OD | 42/F | None | 23 | Initial high-dose CE and slow tapering | CF | 20/20 | Optic disc hyperemia, macular SD | 78 | |
OS | CF | 20/20 | Optic disc hyperemia, macular SD |